IDEXX Laboratories Q2 2025 Earnings Preview: EPS and Revenue Estimates
PorAinvest
viernes, 1 de agosto de 2025, 12:42 pm ET1 min de lectura
IDXX--
The company's strong performance is driven by several factors. The Companion Animal Group (CAG) is expected to have benefited from global net price improvement and higher volumes, with IDEXX VetLab consumables revenue growth likely driven by higher price realization and volume increases. International CAG Diagnostic recurring revenues are also anticipated to have benefited from new business gains, contributing to the robust expansion of IDEXX's premium instrument installed base. The Water and Livestock, Poultry, and Dairy (LPD) segments are also expected to have delivered solid revenues, with the Water segment benefiting from realized price increases and higher volumes, and the LPD division maintaining U.S. momentum [2].
IDEXX Laboratories' innovations, such as the IDEXX Cancer Dx diagnostic panel for canine lymphoma and the CatalystSmartQC Control, have gained commercial traction and are expected to have positively impacted the company's second-quarter revenues. The company's Zacks Rank of #3 and Earnings ESP of +0.34% suggest a higher likelihood of beating estimates [2].
Investors and financial professionals should closely monitor IDEXX Laboratories' earnings announcement for further insights into the company's performance and future prospects.
References:
[1] https://seekingalpha.com/news/4476706-idexx-laboratories-q2-2025-earnings-preview
[2] https://finance.yahoo.com/news/idexx-release-q2-earnings-whats-115600147.html
IDEXX Laboratories is set to announce Q2 2025 earnings on August 4th. The consensus EPS estimate is $3.30 (+9.3% Y/Y) and the consensus revenue estimate is $1.07B (+6.6% Y/Y). Over the last 2 years, IDXX has consistently beaten EPS estimates by an average of 6.4%.
IDEXX Laboratories (NASDAQ: IDXX) is scheduled to release its second-quarter 2025 earnings results on Monday, August 4th, before the market opens. The consensus estimate for earnings per share (EPS) is $3.30, representing a 9.3% year-over-year (Y/Y) increase, while the consensus revenue estimate stands at $1.07 billion, indicating a 6.6% Y/Y growth. Over the last two years, IDEXX has consistently outperformed EPS estimates by an average of 6.4% [1].The company's strong performance is driven by several factors. The Companion Animal Group (CAG) is expected to have benefited from global net price improvement and higher volumes, with IDEXX VetLab consumables revenue growth likely driven by higher price realization and volume increases. International CAG Diagnostic recurring revenues are also anticipated to have benefited from new business gains, contributing to the robust expansion of IDEXX's premium instrument installed base. The Water and Livestock, Poultry, and Dairy (LPD) segments are also expected to have delivered solid revenues, with the Water segment benefiting from realized price increases and higher volumes, and the LPD division maintaining U.S. momentum [2].
IDEXX Laboratories' innovations, such as the IDEXX Cancer Dx diagnostic panel for canine lymphoma and the CatalystSmartQC Control, have gained commercial traction and are expected to have positively impacted the company's second-quarter revenues. The company's Zacks Rank of #3 and Earnings ESP of +0.34% suggest a higher likelihood of beating estimates [2].
Investors and financial professionals should closely monitor IDEXX Laboratories' earnings announcement for further insights into the company's performance and future prospects.
References:
[1] https://seekingalpha.com/news/4476706-idexx-laboratories-q2-2025-earnings-preview
[2] https://finance.yahoo.com/news/idexx-release-q2-earnings-whats-115600147.html

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios